Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of 225Ac-PSMA in metastatic castration-resistant prostate cancer
NL-OMON52446Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ac-225-PSMA in prostate cancer (PCa), sponsored by Erasmus MC. Primary endpoints: Safety and tolerability, Laboratory safety changes and 1 more. Started Mar 2022; status: recruiting.
02
Drugs
Ac-225-PSMA
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON52446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52446.